News

Public · Published

Merck Says Investigational MASH Drug Shows Promise in Midstage Trial

Merck reported positive Phase 2b results for efinopegdutide, an investigational once-weekly treatment for MASH, a chronic liver disease, and liver fibrosis. After 52 weeks, 56% to 63% of treated participants achieved MASH resolution without worsening fibrosis, compared with 13% on placebo; the study met its primary efficacy endpoint.

Published:

Updated:

What happened

Merck reported positive Phase 2b results for efinopegdutide, an investigational once-weekly treatment for MASH, a chronic liver disease, and liver fibrosis. After 52 weeks, 56% to 63% of treated participants achieved MASH resolution without worsening fibrosis, compared with 13% on placebo; the study met its primary efficacy endpoint.

Confirmed

Global impact / market context

If later studies confirm these results, efinopegdutide could add a treatment option for a serious liver disease and give Merck a potential source of future revenue. The reported benefit may support further development, but the drug is still investigational and is not established as an available treatment.

Analyst inference

The results concern a mid-stage trial, which tests a drug before larger studies, and do not establish whether benefits and safety will hold in broader use. Merck said the safety profile was generally consistent with semaglutide, but the article provides no commercial outlook or financial estimates.

Analyst inference

What to watch

  1. Watch for results from later studies showing whether efinopegdutide’s improvement in MASH resolution and fibrosis persists in more participants and over a longer period. Analyst inference
  2. Check whether Merck reports further safety findings, since the article says the profile was generally consistent with semaglutide but gives no specific adverse-event details. Analyst inference
  3. Look for updates on the drug’s development and any regulatory submissions; the article describes efinopegdutide as investigational and reports only Phase 2b results. Analyst inference

Evidence

  • Original source link unavailable